The choice between them should be a clinical decision based on a patient's metabolic profile, treatment history, comorbidities, and prescriber judgment
Since 1990, obesity rates have more than doubled worldwide, driving a corresponding increase in weight-related chronic diseases
Oct 16: Patients with early-stage non-small cell lung cancer (NSCLC) can now rely on just one drugMercks Keytrudabefore and after surgery, in addition to chemotherapy during pre-surgical treatment, after the FDA approved the blockbuster Monday as a continuous regimen for these patients
PMID: 22937864
Realistic timelines for results
[DOI] [PubMed] [Google Scholar] 57.Cazzola M., Calzetta L., Page C., Jardim J., Chuchalin A.G., Rogliani P., Matera M.G